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The Editorial board of Cellular Oncology 
 
 
Ghent, September 1, 2016 
 
 
Dear Dr. Editor, 
 
Please find enclosed our manuscript entitled “Epigenetic sampling effects: nephrectomy 
modifies the clear cell renal cell cancer methylome” for consideration for publication in 
Cellular Oncology as a short communication.  
In a recently accepted paper (Dynamic epigenetic changes to VHL occur with sunitinib in 
metastatic clear cell renal cancer, Stewart et al, Oncotarget), we demonstrated an epigenetic 
change in the VHL gene upon clear cell renal cancer treatment. As pre- and post treatment 
conditions differed in the manner of sampling, we ran an additional study to analyse a 
possible sampling effect (biopsy vs. nephrectomy). Though this was not the case for VHL – 
subject of the previous paper - a clear sampling effect was observed for some loci and also 
appeared to be relevant in the actual treatment study. This implies that sampling procedure 
impacts results in cellular oncology studies. As the most likely underlying cause – hypoxia – 
is relevant in many such studies, and the sampling study is unique in its kind (biopsy 
immediately followed by nephrectomy), we are confident that this paper is of general interest 
to researchers in the field of cellular oncology. 
 
 
Yours sincerely, 
 
Prof. Dr. Tim De Meyer 
Dept. of Mathematical Modelling, Statistics and Bioinformatics 
Ghent University - Belgium 
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  37 
Abstract 38 
 39 
Currently, it is unclear to what extent sampling procedures affect the epigenome. Here, this 40 
phenomenon was evaluated by studying the impact of artery ligation on DNA methylation in 41 
clear cell renal cell cancer. To t his end, DNA methylation profiles between vascularised 42 
tumour biopsy samples and devascularized nephrectomy samples from two individuals were 43 
compared. The relevance of significantly altered methylation profiles was validated in an 44 
independent clinical trial cohort. We found that six genes were differentially methylated in 45 
the test samples, of which four were linked to ischaemia or hypoxia (REXO1L1, TLR4, hsa-mir-46 
1299, ANKRD2). Three of these genes were also found to be significantly differentially 47 
methylated in the validation cohort, indicating that the observed effects are genuine. Based 48 
on these results, we conclude that the impact of sampling procedures in clinical epigenetic 49 
studies should be considered, particularly after inducing hypoxia/ischemia, which occurs in 50 
many oncological surgery procedures through which tissues are harvested for translational 51 
research. 52 
 53 
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  57 
1 Introduction 58 
 59 
The use of clinical samples in epigenetics research has become routine (Ferraro, 2016; Taucher 60 
et al., 2016; Vitiello et al., 2015)[1–3][refs. Cell. Oncol. 39, 295-318, 2016; Cell. Oncol. 39, 195-61 
210, 2016; Cell. Oncol. 38, 17-28, 2015]. However, the nature of the sampling procedures may 62 
significantly compromise the resulting epigenetic profiles, leading to an “epigenetic observer 63 
effect". In renal cell carcinoma (RCC), dynamic molecular changes occur over time and with 64 
therapy, which require serial tissue samples for elucidation [4,5][1, 2]. Despite the 65 
development of standard operating procedures for tissue acquisition and biobanking, less 66 
attention is paid to ensuring constant, robust pre-collection conditions, such as warm 67 
ischaemia time, than to post-collection handling and processing procedures, thus failing to 68 
avoid variation due to pre-analytical factors [6][3]. There are recommended tissue sampling 69 
guidelines from organisations such as the Confederation of Cancer Biobanks, which advise 70 
that warm ischaemia time should be minimised as much as possible prior to freezing of fresh 71 
tissue samples, but this is very difficult to measure and standardise [7][4]. Several studies have 72 
looked at the procurement conditions on RNA biomarker expression and the effect on 73 
previously identified cancer biomarkers [8][5], but so far there have been no such studies on 74 
DNA methylation. 75 
Prolonged ischaemia leads to higher levels of tissue hypoxia, which has been shown to 76 
induce DNA demethylation in e.g. hepatoma cells [9][6]. This demethylation has been shown 77 
to be induced by methionine adenosyltransferase 2A (MAT2A), of which the expression is 78 
positively regulated by HIF-1a [9][6], which in turn is negatively regulated by VHL [10][7]. VHL 79 
plays a crucial role in RCC development [11][8]. Hypoxia, methylation and RCC form, therefore, 80 
an intricate network of which the components cannot be studied separately. Yet, different 81 
RCC sampling procedures might obfuscate the results by influencing the hypoxic conditions. 82 
More than most tumours, RCC sampling is challenging as the majority of the extirpative 83 
procedures deal with minimally invasive approaches. It is well established that changes occur 84 
in mRNA levels with increasing time after renal artery clamping in RCC [12][9]. Here, we 85 
assessed the effect of renal artery clamping on the RCC methylome. 86 
 87 
Patient samples and methods 88 
 89 
Field Code Changed
Formatted: Font: Calibri
Formatted: Font: Calibri, Font color: Black, (Intl) +Body
(Calibri)
Patient-matched sample sets were obtained from two patients who, at the time of open 90 
cytoreductive nephrectomy for metastatic clear cell RCC (ccRCC), had fresh ccRCC tumour 91 
biopsies taken prior to ligation of the renal artery after which matched fresh frozen tumour 92 
samples were harvested following ligation and division of the renal artery and removal of the 93 
kidney as per a previously described approach [5][2]. A total of 12 samples was collected, i.e., 94 
3 biopsy and 3 nephrectomy samples from each patient. These samples were obtained as part 95 
of the Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC) 96 
study (East of Scotland Research Ethics Service REC 1: 10/S1402/33). For validation purposes, 97 
but also to evaluate the potential impact on clinical epigenetics research, matched tumour 98 
samples taken at the time of diagnostic renal tumour biopsy and subsequent nephrectomy 99 
were obtained from 14 patients with metastatic ccRCC. Following primary tumour biopsy, 100 
these patients were treated with three cycles of sunitinib (18 weeks) followed by 101 
cytoreductive nephrectomy after 2 weeks of sunitinib as part of the Upfront Sunitinib 102 
(SU011248) Therapy Followed by Surgery in Patients with Metastatic Renal Cancer: a Pilot 103 
Phase II Study (SuMR; ClinicalTrials.gov identifier: NCT01024205) [13][10 ]. All samples used 104 
in this study are listed in Supplementary file 1. 105 
Extraction of genomic DNA was performed using a Qiagen DNeasy Blood and Tissue 106 
(Qiagen, UK) kit following the manufacturer's instructions. DNA methylation analyses using 107 
MBD sequencing was carried out as described previously [14][11 ]. A MethylCap kit 108 
(Diagenode, Belgium) was used for capturing methylated fragments from 500 ng starting 109 
material. Massively parallel sequencing of these fragments was subsequently performed on 110 
an Illumina HiSeq 2000 machine (Illumina, San Diego, CA, USA). 111 
Raw data files were mapped using BOWTIE to the human reference genome 112 
Hg19/GRCh37, and summarized using an in-house developed Map of the Human Methylome 113 
[15][12 ] consisting of a putative genome-wide overview of potentially methylated loci 114 
(“methylation cores”). Further data analyses were performed using Python 3.4.3 and R 3.2.1. 115 
The Bioconductor quantro software package (1.2) was used to assess quantile normalization 116 
assumptions [16][13 ], whereas the limma software package (3.24.15) was used to identify 117 
regions featured by differential methylation patterns. Prior to limma analysis, the samples 118 
were quantile normalized and transformed using the voom function [17][14 ]. Only 119 
methylation cores that referred to annotated promoter regions (including exon1), and that 120 
had at least an average coverage of one mapped fragment per sample, were withheld for 121 
analysis. Low coverage loci are featured by a too low power to be detected as differentially 122 
methylated, thereby unnecessarily inflating the amount of hypotheses tested, which justifies 123 
their unsupervised removal from the dataset. Regions with a False Discovery Rate (FDR) < 0.05 124 
were selected for further assessment using the sample dataset [13][10 ]. For the validation 125 
dataset, the FDR estimation (Benjamini-Hochberg) was based on the amount of loci to be 126 
validated. 127 
 128 
Results and discussion 129 
 130 
A quantro test was performed to check the suitability of the samples for quantile 131 
normalization, which was used for limma-voom. A p-value of 0.53 was obtained after 1000 132 
permutations, implying that there were no global differences in the distributions between the 133 
non-ischaemic biopsy and ischaemic nephrectomy samples. A limma-voom data analysis was 134 
subsequently performed using quantile normalization. In Table 1 seven regions are listed that 135 
were found to be differentially methylated up to an FDR of 0.05 (Fig 1 ). Only two of these 136 
seven (AC232323.1 and ANKRD2) exhibited a relative hypomethylation in the ischaemic 137 
nephrectomy samples compared to the non-ischaemic samples. In one of these (AC232323.1) 138 
a different region (8325757) exhibited a significant relative hypermethylation. 139 
The differentially methylated regions with a FDR < 0.05 were subsequently subjected 140 
to validation using methylation data obtained from matched biopsy and nephrectomy 141 
samples from the SuMR clinical trial. Three of the seven regions identified in the test set, were 142 
again significantly altered at the same level within the validation cohort (AC232323.1 region 143 
8325757, REXO1L1 and OR6Q1). A binomial test – using the FDR threshold as expected 144 
probability – rejected the null hypothesis that this would have occurred randomly (p = 0.004). 145 
We therefore hypothesise that the shared results between the two studies are caused by 146 
ischaemic conditions. Of the 7 loci identified in the test set, 6 were found to have the same 147 
fold change direction in the validation cohort. However, assuming a 50% random chance of 148 
having the same fold change direction, the number of similar direction of change was not 149 
found to be significant (p = 0.125). A lower FDR cut-off of 10% yielded 36 significant regions, 150 
yet this cut-off was deemed not sufficiently conservative as the fraction that could be 151 
validated in the validation cohort was too low to reject the null hypothesis of significant 152 
overlap (p = 0.085, data not shown). 153 
Methylation meta-analyses have shown that DNA methylation is a critical event in 154 
tumorigenesis [18][15]. It is, therefore, surprising that an analysis of the effect of tissue 155 
procurement on DNA methylation has so far not been performed, as it has in other molecular 156 
analyses. From our test and validation results it is clear that ischaemic conditions, induced as 157 
part of the surgical procedure, may lead to differential methylation. 158 
The results of the study presented here indicate that the RCC methylome may be 159 
modulated following renal artery ligation. Global gene demethylation in samples was not 160 
observed, but consistent demethylation of at least one individual gene (ANKRD2) was found. 161 
These results hold considerable significance for translational methylation research for solid 162 
tumours obtained by extirpative surgery, especially where minimally invasive surgical 163 
approaches are used. The most significantly affected gene, AC232323.1, encodes a long non-164 
coding RNA (lncRNA) product. According to LNCipedia [19][16] this lncRNA is linked to the 165 
second most significantly affected gene, REXO1L1, and has potential direct biological 166 
relevance (http://www.lncipedia.org/db/transcript/lnc-REXO1L2P-1:1). REXO1L1 was found 167 
to be hypermethylated following renal artery clamping. REXO1L1 deletions have been linked 168 
to increased apoptosis under certain conditions [20][17], such as intense hypoxia, which may 169 
underlie the results presented above [21][18]. The third significantly affected gene, TLR4, 170 
plays a crucial role in kidney ischemia/reperfusion injury [22][19], and Hsa-mir-1299 also has 171 
a possible role in apoptosis through interaction with PIM1 [23][20]. The OR6Q1 gene encodes 172 
an olfactory receptor and is, therefore, an unlikely candidate, although it should be noted that 173 
there is evidence for a limited expression in other tissues as well [24][21]. Finally, ANKRD2 174 
belongs to the conserved muscle ankyrin repeat protein (MARP) family. Expression of MARPs 175 
has been found to be induced in response to physiologic stress, injury, hypoxia and 176 
hypertrophy [25,26][22, 23] and the ANKRD2 mRNA level has indeed been found to be 177 
upregulated under specific hypoxic conditions. Our results indicate that this upregulation may 178 
be brought about by demethylation of a specific methylation core. 179 
Despite the test and validation cohorts used, this study should be considered as proof 180 
of principle with a necessarily low power, as it was deemed unethical to expose subjects to an 181 
extra pre-operative percutaneous biopsy procedure without clinical benefit. Also, in the 182 
validation cohort, patients were treated with sunitinib, the time between biopsy and 183 
nephrectomy was longer (20 weeks) and the sequencing depths were generally more shallow, 184 
implying that additional discrepancies between both datasets may have been caused by 185 
treatment, temporal or other technical reasons. 186 
Taken together, our data indicate that in both a test and a validation cohort renal 187 
artery ligation modulates gene methylation in a biologically relevant fashion. As with any 188 
research using surgically resected clinical samples, future methylation studies must be 189 
designed to include robust and well-documented sample procurement techniques in order to 190 
take these findings into account. 191 
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Legend tot the Figure 215 
 216 
Figure 1 Sampling procedure differences. For each of the regions with a FDR < 0.05, boxplots 217 
of the methylation counts are shown. The methylation core region is shown under the gene 218 
label. 219 
 220 
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8325759 AC232323.1 0.731 10.84 1.256e-07 0.0055 
8325735 REXO1L1 -1.184 6.28 1.842e-07 0.0055 
8396394 TLR4 -2.483 3.55 8.634e-07 0.0173 
8371090 hsa-mir-1299 -1.638 4.90  2.028e-06 0.0273 
7046978 OR6Q1 -2.521 3.22 2.269e-06 0.0273 
6996258 ANKRD2 2.249 3.66  3.262e-06 0.0327 
8325757 AC232323.1 -1.242 8.88 4.777e-06 0.0411 
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figure 1 Click here to download line figure samplingProcedureDifferences.pdf 
Supplementary	table	1:	Clinico-pathological	characteristics	of	the	two	test	patients.	
	
Warm	ischemia	time	is	the	time	from	clamping	of	the	renal	artery	to	tumour	sampling	and	
snap	freezing	on	dry	ice.	
	
	
	 	
Clinico-pathological	
Characteristic	 Test	patient	1	 Test	Patient	2	
Age	(years)	 59	 73	
Gender	 Male	 Male	
Fuhrman	grade	 2	 2	
T	stage	 3a	 3a	
M	stage	 1	 1	
Warm	ischemia	time*	(mins)	 55	 60	
Previous	Treatment	
3	cycles	of	Sunitinib	50mg	
once	daily.	Nephrectomy	4	
days	following	cessation.	
None	
supplementary tables Click here to download attachment to manuscript
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Supplementary	table	2:	Clinico-pathological	characteristics	of	the	14	validation	cohort	
patients	all	with	metastatic	ccRCC	and	having	tumour	biopsy	followed	by	sunitinib	therapy	
and	subsequent	cytoreductive	nephrectomy.		
	
Age,	median	(range)	 67	(52-78)	
Male	gender	(%)	 11	(78.6)	
MSKCC	prognostic	risk	(%)	 	
Intermediate	 11	(78.6)	
Poor	 3	(21.4)	
Metastatic	sites	(%)	 	
1-2	 10	(71.4)	
3+	 4	(28.6)	
Clear	cell	tumour	grade,	identified	at	nephrectomy	(%)*	 	
1-2	 7	(50)	
3-4	 7	(50)	
Median	PFS,	months	(95%	CI)	 17.5	(7-21)	
